{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:32Z","timestamp":1760189012287},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,10,22]],"date-time":"2008-10-22T00:00:00Z","timestamp":1224633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1471-2334-8-144","type":"journal-article","created":{"date-parts":[[2008,10,22]],"date-time":"2008-10-22T18:14:05Z","timestamp":1224699245000},"source":"Crossref","is-referenced-by-count":17,"title":["Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children"],"prefix":"10.1186","volume":"8","author":[{"given":"M Isabel","family":"Gonzalez-Tome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Tomas Ramos","family":"Amador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jose Mellado","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Luisa Navarro","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo Rojo","family":"Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo Martin","family":"Fontelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,22]]},"reference":[{"issue":"10","key":"735_CR1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/01.aids.0000131334.38172.01","volume":"18","author":"European Paediatric Lipodystrophy Group","year":"2004","unstructured":"European Paediatric Lipodystrophy Group: Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004, 18 (10): 1443-1451. 10.1097\/01.aids.0000131334.38172.01.","journal-title":"AIDS"},{"issue":"1","key":"735_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00006454-200301000-00018","volume":"22","author":"EG Leonard","year":"2003","unstructured":"Leonard EG, McComsey GA: Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003, 22 (1): 77-84. 10.1097\/00006454-200301000-00018.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"735_CR3","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1542\/peds.111.3.e275","volume":"111","author":"G McComsey","year":"2003","unstructured":"McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study: Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003, 111 (3): e275-281. 10.1542\/peds.111.3.e275.","journal-title":"Pediatrics"},{"issue":"5","key":"735_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","volume":"21","author":"RA Amaya","year":"2002","unstructured":"Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW: Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002, 21 (5): 405-410. 10.1097\/00006454-200205000-00011.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"735_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00006454-200305000-00017","volume":"22","author":"JL Bockhorst","year":"2003","unstructured":"Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, Allen HF: Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J. 2003, 22 (5): 463-465. 10.1097\/00006454-200305000-00017.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"735_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1695-4033(04)78259-4","volume":"60","author":"P Rojo Conejo","year":"2004","unstructured":"Rojo Conejo P, Ramos Amador JT, Garcia Pinar L, Ruano Fajardo C, Sanchez Granados JM, Gonzalez Tome MI, Ruiz Contreras J: Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy. An Pediatr (Barc). 2004, 60 (3): 249-253. 10.1157\/13058075.","journal-title":"An Pediatr (Barc)"},{"issue":"10","key":"735_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/01.aids.0000131334.38172.01","volume":"18","author":"European Paediatric Lipodystrophy Group","year":"2004","unstructured":"European Paediatric Lipodystrophy Group: Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004, 18 (10): 1443-1451. 10.1097\/01.aids.0000131334.38172.01.","journal-title":"AIDS"},{"key":"735_CR8","doi-asserted-by":"crossref","unstructured":"McComsey GA, Leonard E: Metabolic complications of HIV therapy in children. AIDS. 18 (13): 1753-1768. 10.1097\/00002030-200409030-00004. 2004 Sep 3","DOI":"10.1097\/00002030-200409030-00004"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"f51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998, 12: f51-58. 10.1097\/00002030-199807000-00003.","journal-title":"AIDS"},{"key":"735_CR10","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","volume":"160","author":"S Tsiodras","year":"2000","unstructured":"Tsiodras S, Mantzoros C, Hammer S, Samore M: Effect of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch Intern med. 2000, 160: 2050-2056. 10.1001\/archinte.160.13.2050.","journal-title":"Arch Intern med"},{"key":"735_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","volume":"100","author":"D Periard","year":"1999","unstructured":"Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V: Atherogenic dyslipemia in HIV infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation. 1999, 100: 700-705.","journal-title":"Circulation"},{"issue":"5","key":"735_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/00126334-200304150-00003","volume":"32","author":"A Vigano","year":"2003","unstructured":"Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P: Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr. 2003, 32 (5): 482-489. 10.1097\/00126334-200304150-00003.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"735_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJMoa021589","volume":"349","author":"E Martinez","year":"2003","unstructured":"Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. N Engl J Med. 2003, 349 (11): 1036-1046. 10.1056\/NEJMoa021589.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"735_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00126334-200309011-00012","volume":"34","author":"B Clotet","year":"2003","unstructured":"Clotet B, Valk van der M, Negredo E, Reiss P: Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr. 2003, 34 (Suppl 1): 79-84.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"735_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1086\/324629","volume":"34","author":"E Negredo","year":"2002","unstructured":"Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldra A, Balague M, Johnston S, Arno A, Jou A, Tural C, Sirera G, Romeu J, Clotet B: Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002, 34 (4): 504-510. 10.1086\/324629.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"735_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","volume":"16","author":"E Negredo","year":"2002","unstructured":"Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B: Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002, 16 (10): 1383-1389. 10.1097\/00002030-200207050-00010.","journal-title":"AIDS"},{"issue":"3","key":"735_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00126334-200107010-00003","volume":"27","author":"L Ruiz","year":"2001","unstructured":"Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B, Spanish Lipodystrophy Group: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001, 27 (3): 229-236.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","volume":"19","author":"C Fisac","year":"2005","unstructured":"Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005, 19: 917-925. 10.1097\/01.aids.0000171405.46113.bf.","journal-title":"AIDS"},{"issue":"6","key":"735_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/0889222041217374","volume":"20","author":"P Tebas","year":"2004","unstructured":"Tebas P, Yarasheski K, Henry K, Claxton S, Kane E, Bordenave B, Klebert M, Powderly WG: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retrovirus. 2004, 20 (6): 589-594. 10.1089\/0889222041217374.","journal-title":"AIDS Res Hum Retrovirus"},{"issue":"Suppl","key":"735_CR20","first-page":"393","volume":"16","author":"JR Zachetta","year":"1995","unstructured":"Zachetta JR, Plotkin H, Alvarez Figueira ML: Bone mass in children: Normative values for the 2\u201320 years old population. Bone. 1995, 16 (Suppl): 393-399.","journal-title":"Bone"},{"issue":"4","key":"735_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s001980050224","volume":"10","author":"HK Genant","year":"1999","unstructured":"Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barret-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Jhnell O, Johnston CC, Lau EM, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Khaltaev N: Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999, 10 (4): 259-264. 10.1007\/s001980050224.","journal-title":"Osteoporos Int"},{"key":"735_CR22","volume-title":"Grow and adolescence","author":"JM Tanner","year":"1962","unstructured":"Tanner JM: Grow and adolescence. 1962, Oxford. Blackwell Scientific publication, 2","edition":"2"},{"issue":"12","key":"735_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/088922201316912727","volume":"17","author":"AJ Melvin","year":"2001","unstructured":"Melvin AJ, Lennon S, Mohan KM, Purnell JQ: Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses. 2001, 17 (12): 1117-1123. 10.1089\/088922201316912727.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"735_CR24","unstructured":"Castelli-Gattinara G, Amicosante M, Palam P: 3-NRTI HAART simplification in children is effective in maintaining virological and immunological control after 108 weeks. 13th Conference on Retrovirus and Opportunistic Infections. Denver. February 2006. (Abstract 18)"},{"issue":"Suppl 4","key":"735_CR25","first-page":"19","volume":"6","author":"PN Kumar","year":"2001","unstructured":"Kumar PN, Rodriguez-French A, Thompson MA: Prospective study of hyperlipidemia in antiretroviral therapy-naive subjects taking abacavir\/Combivir, Combivir\/nelfinavir, or lamivudine\/stavudine\/nelfinavir(GSK Protocol ESS40002). Antiviral Ther. 2001, 6 (Suppl 4): 19-20.","journal-title":"Antiviral Ther"},{"issue":"15","key":"735_CR26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1097\/00002030-199910220-00035","volume":"13","author":"T Saint-Marc","year":"1999","unstructured":"Saint-Marc T, Touraine JL: The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS. 1999, 13 (15): 2188-2189. 10.1097\/00002030-199910220-00035.","journal-title":"AIDS"},{"issue":"1","key":"735_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","volume":"33","author":"GJ Moyle","year":"2003","unstructured":"Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG: A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003, 33 (1): 22-28.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"735_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1001\/jama.288.2.207","volume":"288","author":"A Carr","year":"2002","unstructured":"Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA: Abacavir substitution for nucleoside analogs in patients with lipoatrophy: a randomised trial. JAMA. 2002, 288: 207-215. 10.1001\/jama.288.2.207.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"735_CR29","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/00002030-200304001-00015","volume":"17","author":"D Scevola","year":"2003","unstructured":"Scevola D, Di Matteo A, Lanzarini P, Uberti F, Scevola S, Bernini V, Spoladore G, Faga A: Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003, 17 (Suppl 1): S123-129.","journal-title":"AIDS"},{"issue":"12","key":"735_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","volume":"15","author":"N Clumeck","year":"2001","unstructured":"Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S, CNA30017 Study Team: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001, 15 (12): 1517-1526. 10.1097\/00002030-200108170-00009.","journal-title":"AIDS"},{"issue":"11","key":"735_CR31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/00002030-199907300-00004","volume":"13","author":"CA Wanke","year":"1999","unstructured":"Wanke CA: Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS. 1999, 13 (11): 1287-1293. 10.1097\/00002030-199907300-00004.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-8-144\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T07:16:09Z","timestamp":1548141369000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-8-144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-8-144","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,22]]},"article-number":"144"}}